Emerging drugs for the treatment of noninfectious uveitis. (3rd July 2019)

• Record Type: Journal Article
• Authors: Pleyer, Uwe; Pohlmann, Dominika; Kardeş, Esra; Poddubnyy, Denis; Rademacher, Judith
• Is Part Of: Expert opinion on emerging drugs. Volume 24:Number 3(2019)
• Page Start: 173
• Page End: 190
• Publication Date: 2019-07-03
• Subjects: Autoimmunity -- biological -- cytokine -- corticosteroid -- kinase inhibitor -- small-molecular-weight-inhibitor -- uveitis; Drugs -- Research -- Handbooks, manuals, etc; Drugs -- Design -- Periodicals; 615.1072
• DOI: 10.1080/14728214.2019.1663823
• Languages: English
• ISSNs: 1472-8214

Abstract

ABSTRACT: Introduction : Uveitis is a leading cause of visual impairment and a significant burden of blindness. Although corticosteroids and conventional immunosuppressive agents have been successfully used, these are non-specific, and their long-term use may induce significant adverse effects. Areas covered : This article discusses existing local and systemic applied treatments for ocular inflammation including corticosteroids, non-biologic, and biologic disease-modifying anti-rheumatic drugs (DMARD). Potential drugs being studied in clinical trials are introduced for both local and systemic use. Expert opinion : Treatment options for uveitis continue to expand. Still, more efforts and research are needed to better understand the mechanisms potentially leading to clinical trials.